Inhibitors of hepatitis b virus

A compound of general formula (I):

• wherein:
• A is a 6-membered aromatic or heteroaromatic ring;
• B is a 6-membered aryl optionally containing one or more N atoms;
• X is H or NR3R4;
• Y is selected from the group consisting of hydrogen, halogen, C1-6alkyl, NH2, NH(C1-6alkyl), N(CH3)2, NHC(O)CH3, OH, saturated or partially unsaturated C3-7cycloalkyl, 5- or 6-membered heteroaryl and CN or is absent;
• with the proviso that, when X is H, Y is selected form the group consisting of NH2, NH(C1-6alkyl), N(CH3)2, NHC(O)CH3;
• R1 and R2 are each independently selected from H, linear or branched C1-6alkyl, saturated or partially unsaturated
• C3-7 cycloalkyl, C3-7heterocycloalkyl and heteroaryl, each of said linear or branched C1-6alkyl, saturated or partially unsaturated C3-7cycloalkyl, C3-7heterocycloalkyl or heteroaryl group being optionally substituted with one or more substituents selected from OH, halogen, NH2, NH(C═O)OC1-6alkyl, NH(C1-6alkyl), C1-6alkyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C1-6hydroxyalkyl, 5- or 6-membered heteroaryl, C(═O)C1-6alkyl, C(═O)OC1-6alkyl, OC1-6alkyl, O(CH2)nC3-10cycloalkyl and O(CH2)nC3-10 heterocycloalkyl;
• or R1 and R2 taken together form with the N atom to which they are attached a saturated or partially unsaturated 3-10 membered heterocyclic ring optionally containing another heteroatom selected from N, O and S, said saturated or partially unsaturated 3-10 membered heterocyclic ring being optionally substituted with one or more substituents selected from OH, halogen, C1-6alkyl, C1-6haloalkyl and (CH2)nR5;
• each occurrence of n is independently 0, 1, 2, 3 or 4;
• R3 and R4 are each independently H, or linear or branched C1-3alkyl optionally substituted with one or more groups selected from halogen, NH2, NHC1-6alkyl, N(C1-6alkyl)2, NH(C═O)C1-6alkyl, NH(C═O)OC1-6alkyl, OC1-6alkyl, O(CH2)nC3-10cycloalkyl and O(CH2)nC3-10heterocycloalkyl, with the proviso that NR3R4 does not form a saturated, partially saturated or unsaturated heterocyclic ring;
• R5 is selected from the group consisting of OH, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, CN, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, heterocyclic ring, aryl and heteroaryl;
• Ra is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O) CH3, OH and CN;
• or is absent;
• Rb is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN;
• or is absent;
• Rc is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN;
• or is absent;
• Rd is selected from the group consisting of hydrogen, halogen, C1-3alkyl, haloC1-3alkyl, C1-3alkoxy, haloC1-3alkoxy, NH2, NH(CH3), N(CH3)2, NHC(O)CH3, OH and CN;
• or is absent;
• Re is selected from the group consisting of hydrogen, halogen, C1-3alkyl;
• or is absent;
• Rf is hydrogen, halogen, C1-3alkyl;
• or is absent;
• provided that the compound is not 2-amino-N-(4-chloro-2-methylphenyl)-5-sulfamoylbenzamide or N-(2-methoxyphenyl)-2-(methylamino)-5-(piperidin-1-ylsulfonyl)benzamide;
• and pharmaceutically acceptable salts, tautomers, isomers, stereoisomers thereof.